Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Axelsson

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Circulation|April 7, 2018
Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic CardiomyopathyAnna Axelsson Raja, Hoshang Farhad, Anne Marie Valente, et al.
Circulation. Heart Failure|June 27, 2022
Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical TrialHenning Bundgaard, Anna Axelsson Raja, Kasper Iversen, et al.
Journal of the American Heart Association|May 20, 2018
MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) SubstudyAlexander C Falkentoft, Rasmus Rørth, Kasper Iversen, et al.
ESC Heart Failure|August 9, 2020
ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patientsTiina Heliö, Perry Elliott, Juha W Koskenvuo, et al.
Diabetes Care|October 15, 2024
Maternal Diabetes and Cardiac Left Ventricular Structure and Function in the Infant: A Copenhagen Baby Heart StudyJonas Ghouse, Magdalena Hansson, Ruth Ottilia B Vøgg, et al.
European Journal of Epidemiology|October 12, 2018
Copenhagen Baby Heart Study: a population study of newborns with prenatal inclusionAnne-Sophie Sillesen, Anna Axelsson Raja, Christian Pihl, et al.
Circulation|March 9, 2026
Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic CardiomyopathyChristoffer R Vissing, Anna Axelsson Raja, Adam S Helms, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2022
Ablation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse modelAnna Axelsson Raja, Hiroko Wakimoto, Daniel M DeLaughter, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Circulation|April 7, 2018
Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic CardiomyopathyAnna Axelsson Raja, Hoshang Farhad, Anne Marie Valente, et al.
Circulation. Heart Failure|June 27, 2022
Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical TrialHenning Bundgaard, Anna Axelsson Raja, Kasper Iversen, et al.
Journal of the American Heart Association|May 20, 2018
MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) SubstudyAlexander C Falkentoft, Rasmus Rørth, Kasper Iversen, et al.
ESC Heart Failure|August 9, 2020
ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patientsTiina Heliö, Perry Elliott, Juha W Koskenvuo, et al.
Diabetes Care|October 15, 2024
Maternal Diabetes and Cardiac Left Ventricular Structure and Function in the Infant: A Copenhagen Baby Heart StudyJonas Ghouse, Magdalena Hansson, Ruth Ottilia B Vøgg, et al.
European Journal of Epidemiology|October 12, 2018
Copenhagen Baby Heart Study: a population study of newborns with prenatal inclusionAnne-Sophie Sillesen, Anna Axelsson Raja, Christian Pihl, et al.
Circulation|March 9, 2026
Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic CardiomyopathyChristoffer R Vissing, Anna Axelsson Raja, Adam S Helms, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2022
Ablation of lysophosphatidic acid receptor 1 attenuates hypertrophic cardiomyopathy in a mouse modelAnna Axelsson Raja, Hiroko Wakimoto, Daniel M DeLaughter, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
Pageof 10